Sutro Biopharma

Historical price data

Sutro Biopharma is redefining cancer therapy through its innovative cell-free protein synthesis platform, XpressCF®, which allows for the rational design of optimized antibody-drug conjugates (ADCs). The company's core strategy involves developing single- and dual-payload ADCs aimed at overcoming treatment resistance and expanding the range of treatable tumors. With a public listing on NASDAQ and a leadership team rich in biotech experience, Sutro is advancing a clinical pipeline while leveraging its platform through strategic collaborations to create meaningful breakthroughs for patients.

Proprietary cell-free protein synthesis platform (XpressCF®) that enables precise design and manufacturing of novel protein therapeutics, including site-specific, homogeneous antibody-drug conjugates (ADCs) and dual-payload ADCs.

7 drugs in pipeline

Total raised: $394M

Sutro competes in the crowded ADC space against large pharma (e.g., AstraZeneca, Gilead) and biotech peers. Its main differentiation is the XpressCF® platform, which enables precise, homogeneous ADC construction and the novel dual-payload approach, aiming to overcome resistance mechanisms that limit current therapies.